Homology Medicines Inc

NASDAQ:FIXX  
1.56
-0.09 (-5.46%)
Other Pre-Announcement

Homology Medicines Reports Fourth Quarter And Full Year 2021 Results

Published: 03/23/2022 20:45 GMT
Homology Medicines Inc (FIXX) - Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights.
Q4 Loss per Share $0.59.
Received $130 Million Non-dilutive Capital That Significantly Extends Cash Runway.
Q4 Earnings per Share View $-0.59 -- Refinitiv Ibes Data (analyst estimates).
Updates Guidance on Phenix Gene Therapy Trial for Pku.
Program Update on Pheedit is Still Expected by Year-end 2022.
Homology Medicines, on Phenix Trial, Says Estimates More Time Will Be Needed to Submit, Receive Feedback on Proposed Clinical Risk-mitigation Strategy.
Now Expects to Provide a Program Update When Path Forward is Established With FDA on Phenix Trial.